Renaissance Technologies LLC raised its position in shares of Natus Medical Incorporated (NASDAQ:BABY) by 226.0% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 149,294 shares of the medical equipment provider’s stock after buying an additional 103,494 shares during the period. Renaissance Technologies LLC’s holdings in Natus Medical were worth $5,860,000 at the end of the most recent quarter.
Several other hedge funds have also recently bought and sold shares of the stock. Ameritas Investment Partners Inc. purchased a new stake in Natus Medical during the first quarter valued at $110,000. Victory Capital Management Inc. boosted its position in Natus Medical by 94.0% in the first quarter. Victory Capital Management Inc. now owns 3,184 shares of the medical equipment provider’s stock worth $125,000 after buying an additional 1,543 shares during the last quarter. State of Alaska Department of Revenue boosted its position in Natus Medical by 1.7% in the first quarter. State of Alaska Department of Revenue now owns 3,630 shares of the medical equipment provider’s stock worth $142,000 after buying an additional 60 shares during the last quarter. San Francisco Sentry Investment Group CA bought a new position in Natus Medical during the first quarter worth $216,000. Finally, Karp Capital Management Corp bought a new position in Natus Medical during the first quarter worth $242,000. 93.86% of the stock is owned by institutional investors and hedge funds.
Shares of Natus Medical Incorporated (NASDAQ BABY) traded up 1.36% during mid-day trading on Friday, hitting $33.55. 350,321 shares of the stock traded hands. The stock has a market cap of $1.09 billion, a P/E ratio of 58.15 and a beta of 0.93. Natus Medical Incorporated has a 12-month low of $32.83 and a 12-month high of $44.39. The firm’s 50 day moving average price is $36.43 and its 200-day moving average price is $36.70.
Natus Medical (NASDAQ:BABY) last announced its quarterly earnings data on Wednesday, July 26th. The medical equipment provider reported $0.34 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.33 by $0.01. Natus Medical had a return on equity of 12.09% and a net margin of 4.20%. The company had revenue of $122.20 million for the quarter, compared to analysts’ expectations of $121.99 million. During the same quarter in the prior year, the business posted $0.39 EPS. The business’s revenue was up 27.3% compared to the same quarter last year. Analysts predict that Natus Medical Incorporated will post $1.70 earnings per share for the current year.
COPYRIGHT VIOLATION WARNING: “Renaissance Technologies LLC Has $5.86 Million Stake in Natus Medical Incorporated (BABY)” was posted by StockNewsTimes and is the property of of StockNewsTimes. If you are accessing this piece on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark law. The correct version of this piece can be viewed at https://stocknewstimes.com/2017/08/11/renaissance-technologies-llc-buys-103494-shares-of-natus-medical-incorporated-baby-updated.html.
A number of equities research analysts have issued reports on BABY shares. TheStreet lowered shares of Natus Medical from a “b” rating to a “c+” rating in a report on Thursday, April 27th. Zacks Investment Research upgraded shares of Natus Medical from a “sell” rating to a “hold” rating in a research note on Tuesday, June 27th. BidaskClub lowered shares of Natus Medical from a “hold” rating to a “sell” rating in a research note on Tuesday, August 1st. Finally, Benchmark Co. reissued a “buy” rating and set a $48.00 price objective (down from $55.00) on shares of Natus Medical in a research report on Monday, May 1st. Three equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and one has assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus price target of $45.00.
In related news, insider James B. Hawkins acquired 4,000 shares of the company’s stock in a transaction dated Thursday, June 15th. The shares were bought at an average price of $33.98 per share, for a total transaction of $135,920.00. Following the purchase, the insider now directly owns 578,023 shares in the company, valued at approximately $19,641,221.54. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Doris Engibous sold 5,000 shares of the company’s stock in a transaction that occurred on Thursday, May 25th. The stock was sold at an average price of $32.68, for a total value of $163,400.00. Following the sale, the director now owns 22,650 shares in the company, valued at approximately $740,202. The disclosure for this sale can be found here. Corporate insiders own 5.50% of the company’s stock.
About Natus Medical
Natus Medical Incorporated is a provider of newborn care and neurology healthcare products and services used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases and balance and mobility disorders.
Receive News & Ratings for Natus Medical Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.
